Free Trial

Verve Therapeutics (VERV) Competitors

$5.60
+0.06 (+1.08%)
(As of 05/22/2024 ET)

VERV vs. ANL, KRRO, ESPR, FULC, PEPG, OCS, APLT, ANNX, TBPH, and NGNE

Should you be buying Verve Therapeutics stock or one of its competitors? The main competitors of Verve Therapeutics include Adlai Nortye (ANL), Korro Bio (KRRO), Esperion Therapeutics (ESPR), Fulcrum Therapeutics (FULC), PepGen (PEPG), Oculis (OCS), Applied Therapeutics (APLT), Annexon (ANNX), Theravance Biopharma (TBPH), and Neurogene (NGNE). These companies are all part of the "pharmaceutical preparations" industry.

Verve Therapeutics vs.

Adlai Nortye (NASDAQ:ANL) and Verve Therapeutics (NASDAQ:VERV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, community ranking, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Adlai Nortye has higher earnings, but lower revenue than Verve Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adlai NortyeN/AN/AN/AN/AN/A
Verve Therapeutics$11.76M39.98-$200.07M-$2.87-1.95

Adlai Nortye currently has a consensus price target of $30.00, suggesting a potential upside of 135.29%. Verve Therapeutics has a consensus price target of $33.00, suggesting a potential upside of 489.29%. Given Adlai Nortye's higher possible upside, analysts plainly believe Verve Therapeutics is more favorable than Adlai Nortye.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adlai Nortye
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Verve Therapeutics
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.75

In the previous week, Verve Therapeutics had 7 more articles in the media than Adlai Nortye. MarketBeat recorded 8 mentions for Verve Therapeutics and 1 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.53 beat Verve Therapeutics' score of 0.00 indicating that Verve Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Adlai Nortye
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Verve Therapeutics
4 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Verve Therapeutics received 14 more outperform votes than Adlai Nortye when rated by MarketBeat users. However, 100.00% of users gave Adlai Nortye an outperform vote while only 46.15% of users gave Verve Therapeutics an outperform vote.

CompanyUnderperformOutperform
Adlai NortyeOutperform Votes
4
100.00%
Underperform Votes
No Votes
Verve TherapeuticsOutperform Votes
18
46.15%
Underperform Votes
21
53.85%

Adlai Nortye has a net margin of 0.00% compared to Adlai Nortye's net margin of -1,226.51%. Verve Therapeutics' return on equity of 0.00% beat Adlai Nortye's return on equity.

Company Net Margins Return on Equity Return on Assets
Adlai NortyeN/A N/A N/A
Verve Therapeutics -1,226.51%-37.35%-29.31%

35.2% of Adlai Nortye shares are held by institutional investors. Comparatively, 97.1% of Verve Therapeutics shares are held by institutional investors. 19.3% of Verve Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Verve Therapeutics beats Adlai Nortye on 8 of the 13 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VERV vs. The Competition

MetricVerve TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$465.17M$6.84B$5.13B$8.04B
Dividend YieldN/A2.73%2.80%3.92%
P/E Ratio-1.9510.01121.6714.41
Price / Sales39.98251.072,467.0867.53
Price / CashN/A35.4535.9231.82
Price / Book0.815.795.414.59
Net Income-$200.07M$141.65M$105.63M$214.11M
7 Day Performance-12.23%-0.60%-0.66%-0.01%
1 Month Performance-18.60%3.20%3.40%3.96%
1 Year Performance-66.49%-5.71%5.73%8.02%

Verve Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ANL
Adlai Nortye
0.887 of 5 stars
$12.75
flat
$30.00
+135.3%
N/A$470.48MN/A0.00127News Coverage
Positive News
Gap Down
KRRO
Korro Bio
3.0877 of 5 stars
$50.80
-7.0%
$122.50
+141.1%
N/A$470.92M$14.07M0.00101Analyst Forecast
Positive News
Gap Up
ESPR
Esperion Therapeutics
3.3915 of 5 stars
$2.41
-2.8%
$9.33
+287.3%
+43.4%$456.60M$116.33M-2.43240Analyst Forecast
Analyst Revision
FULC
Fulcrum Therapeutics
2.6936 of 5 stars
$7.64
-0.8%
$15.57
+103.8%
+151.1%$474.83M$2.81M-4.7776Analyst Forecast
Options Volume
Analyst Revision
PEPG
PepGen
1.8541 of 5 stars
$13.89
+3.0%
$24.67
+77.6%
-2.4%$450.31MN/A-4.2764Gap Up
OCS
Oculis
0.9621 of 5 stars
$11.90
-0.8%
$30.17
+153.5%
-6.3%$481.95M$980,000.00-6.6936
APLT
Applied Therapeutics
4.5552 of 5 stars
$4.24
+1.0%
$11.00
+159.4%
+192.3%$484.51M$9.99M-2.3025Positive News
ANNX
Annexon
2.8681 of 5 stars
$4.80
+2.6%
$14.14
+194.6%
-18.1%$443.57MN/A-3.2771
TBPH
Theravance Biopharma
1.6876 of 5 stars
$9.12
+0.2%
$20.50
+124.8%
-18.1%$443.51M$57.42M-10.60359Analyst Upgrade
NGNE
Neurogene
1.3395 of 5 stars
$32.52
-4.4%
$47.25
+45.3%
N/A$441.45MN/A0.0091

Related Companies and Tools

This page (NASDAQ:VERV) was last updated on 5/23/2024 by MarketBeat.com Staff

From Our Partners